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Introduction
Glioblastoma is one of the most intractable tumors among human malignancies. 1 The median survival of patients with glioblastoma is less than 1 year, and only 5% of patients survive longer than 5 years. Complete cure of this disease remains impossible despite combination treatment with surgery, radiotherapy and conventional chemotherapy. [2] [3] [4] [5] New therapeutic strategies such as gene therapy must be found in order to improve the prognosis. [6] [7] [8] In the absence of a universal molecular abnormality identified in glioma until now, 9 ,10 gene therapy using 'suicide' genes is potentially applicable to all types of brain tumors, regardless of their histological subtypes. The herpes simplex virus thymidine kinase (HSVtk) gene is a 'suicide' gene that has been extensively evaluated for the treatment of brain tumors. 8, 11, 12 It converts the nontoxic nucleoside analogue ganciclovir (GCV) into a phosphorylated compound which inhibits DNA polymerase and leads to cell death. [13] [14] [15] [16] The HSVtk/GCV system is known for its antitumor effects in vivo in experimental models of brain tumor, 8, [17] [18] [19] [20] [21] [22] liver metastases, been treated. Furthermore, other studies have questioned the potential efficacy of such a HSVtk/GCV strategy for treatment because of its low curative effect or recurrence of tumors at the end of GCV therapy. 11, 25, [28] [29] [30] In view of the contradictory results in the literature, it was important to reassess the HSVtk/GCV system efficacy using a more clinically relevant situation. In order to avoid the problems associated with gene transfer which could explain some of these contradictory results, we used a completely and functionally characterized C6 cell line permanently expressing the HSVtk gene (C6TK).
The goals of our study were: (1) to reassess the HSVtk/GCV system efficacy in vivo using a fully characterized C6TK cell line; (2) to analyze the potential efficacy of this system to cure large (15 days) established tumors; and (3) to monitor the efficacy of the HSVtk/GCV system on tumor growth, using a sequential magnetic resonance imaging (MRI) analysis.
Results
Characterization of C6TK cell line from gene to protein To establish C6 cell clones that permanently express the HSVtk gene, cells were transfected by a plasmid (pUT 599) containing HSVtk (therapeutic gene) and shble (selection gene). The selected clone is referred to as C6TK cells. Before using this cell line for in vivo experiments, an extensive characterization from gene to protein was performed to test the function of the C6TK cell line.
Southern blot analysis showed that C6TK cell clone contained a single copy of the HSVtk gene and tk mRNA was detected by RT-PCR analysis (Figures 1a and 1b) . Western blot analysis, using rabbit anti-HSV-TK antiserum, confirmed the presence of TK-Shble fusion protein in this clone (Figure 1c) . TK activity was first tested by in vitro GCV sensitivity; 99% C6TK cells were killed by 20 m GCV in 10 days. TK activity was also measured by an enzymatic assay which was performed to optimize phosphorylated GCV formation. We found that HSV-TK activity was linear with respect to time and protein concentrations. TK activity was 12.6 pmoles of phosphorylated GCV/h/mg of protein in C6TK cells as compared with C6 cells in which no activity was detected.
In order to control the tumorigenicity of the C6TK cell line used in our study, 10 athymic nude mice were inoculated subcutaneously with tumor cells. All tumors (10/10) were found to grow progressively in animals, inducing their death similarly as observed with C6 cells.
Effect of the HSVtk/GCV system on experimental gliomas: early versus late GCV delivery In short-term studies, 32 rats were killed at the end of GCV treatment, 24 or 25 days after tumor cell implantation. This time-course was selected because enlarging tumors often kill the animals close to this time (median survival time was 25.9 ± 7.3 days). As illustrated in Table  1 and Figure 2 , histological staining of control rat brains injected with C6 cells both GCV-treated (G2, n = 6) or not (G1, n = 8), and brains injected with nontreated C6TK cells (G3, n = 6), showed large tumors invading the hemisphere. Only small residual necrotic cells were present in the rats injected with C6TK cells, GCV treated from day 1 (G4, n = 8) as well as those treated from day 10 (G5, n = 5). As shown in Figure 3 , we observed that GCV treatment did not significantly affect (P Ͼ 0.05) C6 tumor size. The mean tumor volume measured in the control groups ) and G5 (20 ± 10 mm 3 ) were significantly different (P Ͻ 0.05) from those measured in control rats, about 8 (G4) and 12 (G5) times smaller than those in the nontreated C6TK group (G3). Immunohistological studies using specific antibodies showed a cellular inflammatory response involving macrophages, CD4
+ and CD8 + T lymphocytes surrounding the necrotic cells in GCV-treated C6TK tumors. Similar staining was observed in nontreated C6TK tumors. In order to analyze the ability of the intracellular marker Shble to induce cellular inflammatory response, the C6Shble cell line which permanently expresses the Shble gene was used to produce experimental gliomas. Similarly, the presence of macrophages, CD4
+ and CD8 + T lymphocytes was detected on 24-day established tumors. In the C6 control group, the presence of a few macrophages was also detected, but no CD4 or CD8 infiltration. Immunohistological staining using specific antibody against factor VIII, present on blood vessels showed a strong reactivity in tumors at day 10 ( Figure 4 ) which was not observed earlier.
Effect of GCV treatment on large (15 days) experimental C6TK gliomas: long-term experiments and nuclear magnetic resonance imaging We then investigated whether GCV was able to improve the survival rate of rats implanted with C6TK cells using sequential NMR imaging at days 14, 28 and 50 after cell inoculation. Fifty-five rats were used for this experiment.
Survival analysis:
The survival analysis showed that all C6-inoculated rats (G6, n = 10) died of intracerebral progressive tumor growth on average at day 25.9 ± 7.3 (Table 1 and Figure 5 ). In the C6TK-inoculated rats without treatment, (G7 and G9) 40% of rats survived until they were killed (day 50) in group 7 (n = 10) and 30% longer than 1 year in group 9 (n = 10) ( Figures 5 and 6 ). Thus, rats inoculated with the C6TK cell line survived longer than those with the C6 (P Ͻ 0.001, log rank test). In the GCV-treated rats (G8 and G10) from day 15 to 34, one of 10 rats died at day 29 after cell inoculation, 90% of rats (G8, n = 10) survived until they were killed (day 50). In group 10 (n = 10), which was used for long-term survival evaluation, 60% survived longer than 1 year and 40% died at day 57 ± 8.8. Analysis of survival data showed that rats inoculated with the C6TK cell line and followed by GCV treatment (G8 and G10) survived longer than the two control groups (P Ͻ 0.001, log rank test). Therefore, GCV treatment in rats implanted with large tumors was able to achieve a long-term survival of over 12 months twice that of control group G9.
NMR imaging time-course: The NMR imaging timecourse was performed to visualize the growth of C6 and C6TK tumors at days 14, 28 and 50 after inoculation. The tumor sizes of C6-inoculated rats (G6) increased progressively until death ( Figure 7 ). All GCV-untreated C6TK tumors grew progressively like C6 tumors until day 28. Then, two different patterns were observed in this group between days 28 and 50: 60-70% of tumors caused animal death at day 32 ± 9.2 ( Figure 7a ) and 30-40% of tumors decreased in size (Figure 7b ). In this later case, long-term follow up over 1 year showed no regrowth of tumors. In the C6TK group treated from days 15 to 34, all tumors were present on day 14. Thereafter, between day 28 and day 50, 90% of these tumors decreased in size. This phenomenon continued until the end of the experimental period for 50 days after cell implantation ( Figure  7) . Then, 60% continued to decrease in size until they completely disappeared. No regrowth was detected over one year. In 40% of cases, tumors grew slowly inducing animal death several weeks after the end of GCV therapy ( Figure 6 ).
Resistance to GCV treatment: When appropriate, the relapsing C6TK brain tumors were re-established in culture in order to study their escape from the in vivo GCV treatment. Three tumors were excised and cells replated. In one of these, referred to as R1, sensitivity to GCV was lost in vitro, the HSVtk gene and mRNA were detected by Southern blot and RT-PCR analysis. However, TK protein was not detected by Western blot. In another tumor, referred to as R2, GCV sensitivity in vitro was partially retained, the HSVtk gene, tk mRNA and TK protein were detectable. However, no TK activity was detected by the enzymatic assay (Figure 8 ). The third tumor re-plated did not grow in culture and no analysis was done.
Discussion
Many contradictory results have recently been published in the field of thymidine kinase 'suicide' gene therapy, questioning the clinical interest of this new antitumor treatment. 11, 25, [28] [29] [30] Furthermore, the design of most experimental studies in animals has involved microscopic tumor formations treated early, only a few days after cell inoculation. 8, [17] [18] [19] [20] [21] [22] The recent publication of the first human trial adds to the concerns in this field, however, the main problem could be the low transfection efficiency observed in vivo with retroviral vectors. 31, 32 To bypass the problems of transfection efficiency and to obtain a clear answer about the potential therapeutic effect of the TK/GCV system, we used a stable C6TK cell line previously transfected in vitro. This cell line was charac- terized from gene to protein including a tumorogenicity assay in athymic nude mice and HSVtk enzymatic activity. It is clearly evident that extensive variations can be observed between different clones 33, 34 and cell types used. 35, 36 Some negative results could be due then to a low functionally efficient HSVtk cell line or a positive therapeutic effect could be due to the loss of tumorigenicity of the selected clone. 17, 37 Therefore, it is important to validate published results by a complete assessment of HSVtk functionality. In vitro GCV killing is not correlated with in vivo GCV response but with TK activity, which is probably the best test to analyze the in vivo efficiency. 33, 34 Therefore, the main goal of this study was to design a different experimental strategy, clinically more relevant, to test the efficiency of the TK/GCV system at the preclinical level. The C6 glioma model 38, 39 consists of the injection of tumoral cells into the caudate nucleus, which grow exponentially after day 8 and on average kills the rats at day 25. 40 In contrast to previous studies, we chose to treat tumors at day 15 when they present a macroscopic size, high infiltration and high angiogenesis, which is similar to what is observed in human tumors. 39 Since GCV therapy was started in this series at an already advanced stage of tumor development (day 15), and as its duration (15 days) extended beyond the average survival (25 days), it was evident that if it was effective on a large tumor, it occurred with the potential risk of mass effect. These modifications might be deleterious even in the presence of a therapeutic antitumoral response. This prompted us to use NMR imaging as indispensable monitoring to follow the change of tumor sizes.
As a first step, we analyzed during short-term experiments, whether late GCV instead of early GCV treatment induced a different therapeutic response. Tumor volumes were measured at the end of GCV therapy. The results indicate that GCV administered (50 mg/kg twice a day) at day 1 or at day 10 after tumor cell inoculation significantly reduces the size of established C6TK tumors.
These results are in agreement with those of other authors 8, 12, [17] [18] [19] [20] 22 who have reported the efficacy of the TK/GCV system in vivo. Surprisingly, the mean tumor sizes were not significantly (P Ͻ 0.05) different when the treatment was started on day 1 or day 10 after tumor cell implantation. A possible explanation could be related to angiogenesis. In vivo bystander effect has been tentatively explained by a cytotoxic effect on intratumoral vascular formations. 41 Immunohistological studies with a specific antibody against factor VIII, present on blood vessels showed a strong reactivity in tumors at day 10 which was not observed earlier. Therefore, higher angiogenesis could explain a better GCV delivery as well as a higher bystander effect. 42 This is positive with respect to human trials, as high grade astrocytomas always harbor an important angiogenesis ratio. 43 However, we have to be careful in the extrapolation of results obtained in animal models to gliomas in human patients.
Long-term experiments (over 1 year), revealed that administration of GCV to 15-day established C6TK tumors, improved (log rank test, P Ͻ 0.001) the survival of rats significantly by an additional 30% while all control C6-inoculated rats died from growing tumors. The efficacy of HSVtk without GCV treatment using 9L tumor cells has been previously reported. 37 The regression observed in one-third of GCV untreated C6TK tumors was not due to nondevelopment of tumors since NMR imaging showed all C6TK grew progressively. This positive effect was observed as a late and slow process. Immunohistological staining performed in short-term experiments indicates the presence of macrophages, CD4 + and CD8
+ T lymphocyte infiltrates. These results are in agreement with other data previously reported 37 which demonstrated that neomycin phosphotransferase, an intracellular selectable marker, can inhibit tumor growth of 9L cells. Similarly, expression of the nuclear LacZ protein has been demonstrated to induce an immune antitumoral response. 44 In addition, implantation of tumors in athymic nude mice showed that all C6TK tumors grew progressively and no tumor regression appeared before death. Taken together, these results could suggest that tumor regression obtained in immunocompetent host rats may be due to the development of an immune response. In a recent study 38 supporting this suggestion, the authors demonstrated that the combined expression of IL-4 and HSVtk inhibited tumor growth in immunocompetent animals more effectively than in nude mice. As has been shown by NMR imaging, all surviving rats (60%) displayed tumor regression between days 15 and 28 after cell implantation. These results are partially in contrast with the survival (100% at 90 days) observed by Barba et al. 17 This difference might be due to the cell line used (9LTK versus C6TK), the time separating the implantation of tumor cells and the beginning of GCV treatment (3 days for Barba and 15 days in our study) or the duration of the experiment (3 months versus 1 year) . Nevertheless, they are in agreement with several studies which have reported cases of TK/GCV resistance. 11, 28, 30, 35, 38 We observed 40% tumor recurrence after day 50. This clearly illustrates that 50 days are not enough to assess the longterm curative effect. Analysis of two of three relapsing tumors indicated that non-responsiveness to in vivo GCV treatment was due to a loss of TK protein or to an inactive protein. This observation might be complementary to the results reported by others 24, 37, 45 showing that relapsing tumors lost the HSVtk gene or its expression. This in vivo unresponsiveness could also be explained by the late effect of GCV on large tumor formations. We used NMR imaging as mandatory monitoring of tumor evolution, which confirms that the curative effects were not due to lack of development of the tumor because all regressive tumors were previously observed as large tumors. This also suggests that the therapeutic effect on large tumor formations was a slow process without mass effect and could be explained by the apoptotic feature of cell death observed with 'suicide' genes. 46, 47 However, edematous reactions have been reported in human trials, 31 which could be explained by the use of murine xenogenic and immunogenic packaging cell lines related to the vector rather than to the HSVtk strategy.
In conclusion, our study demonstrates that late GCV delivery is as efficient as early delivery, probably because of higher angiogenesis on large tumor formations. Moreover, using serial MRI, we demonstrate that large tumor formations which could have clinical relevance to human gliomas, could be cured efficiently using the HSVtk/GCV strategy. The efficacy and safety of this procedure makes it promising for human gliomas.
Materials and methods

Cell culture
The C6 rat glioma cell line was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 4 mm glutamine and antibiotics (50 mg/ml streptamycin and 50 U/ml penicillin). Incubation was carried out at 37°C in a humidified 5% CO 2 95% air atmosphere. The cell lines designated as C6TK and C6Shble were established by transducing C6 cells with pUT 599 and pUT 614 plasmids (Cayla, Toulouse, France) respectively. 48 The HSVtk shble fusion gene in pUT 599 and the shble gene in pUT 614 are driven by the viral herpes simplex thymidine kinase promoter and the viral polyoma Py F441 enhancer. The shble gene from Streptoalloteichus hindustanus encodes a protein that confers resistance to antibiotics zeocin and phleomycin. 49 The cultures were maintained under zeocin (400 g/ml, Cayla) for 1 month to select clones carrying the HSVtk and shble genes for C6TK cells and shble gene for C6Shble cells.
Animals
Experiments were performed on Sprague-Dawley female rats (weight 180-200 g) housed in an environmentally controlled animal room. Food and water were provided ad libitum.
Experimental brain tumor model
All implantation surgery was performed using classical stereotactic techniques, as previously described. 40, 50 Briefly, under general anesthesia with 4% chloral hydrate i.p., the rat was placed in a stereotactic frame and fixed with two ear bars. Skin and periosteum were opened and a burr hole was drilled at the coordinates for the right caudate nucleus (1 mm anterior and 3 mm lateral to bregma). The cell suspension (10 4 cells in 10 l DMEM supplemented with 10% FCS 1% agarose) was inoculated 5.5 mm below the dura using a Hamilton microsyringe connected to the micromanipulator of the stereotactic apparatus, the needle was left in place for 5 min and slowly withdrawn. Agarose was dissolved by heating at 50°C in DMEM and then cooled to 37°C before adding cells. The suspension cells were kept no more than 30 min in order to preserve the viability of cells. They were used to prevent diffusion of cells out of the injection site.
19,40
Southern blot Samples (10 g) of total cellular DNA, prepared from C6 and C6TK cell lines using DNAzol reagent, were run on a 0.7% agarose gel. DNA was transferred to an Amersham Hybond-N nylon membrane (Amersham, Les Ullis, France) and hybridized with 32 P dATP-labeled probe containing HSVtk gene.
RT-PCR
Total RNA was isolated with Triazol Reagent (Life Technologies, Cergy Pontoise, France). After reverse transcription with oligo (dT) primer (Pharmacia First-Stand cDNA Synthesis Kit), cDNA was amplified by PCR (30 cycles: 1 min at 94°C, 1 min at 55°C, 1 min at 72°C) using primers complementary to the coding sequence of HSVtk nucleotides 305-352 (5Ј CATGACCGGTCCAGTGTGCTG GCGCCTAGT GTTGACAATTAATCATCG 3') and nucleotides 1506-1553 (5' CATGGAATTCGCGGCCGC TCAATTAGCTCCGCTGATCATCTCACGGGC 3Ј).
Western blot detection of the TKShble fusion protein Sixty micrograms of cell lysate protein from C6 or C6TK cells were run on a 12% SDS-PAGE and transferred on to PVDF membrane (Millipore, Saint Quentin, France). After blocking for 1 h in 1% Boehringer blocking solution, the membrane was incubated for 1 h with serum directed against HSV/TK protein diluted (1/2000) in 0.5% blocking solution. After three PBS washes, the membrane was incubated with biotinylated anti-rabbit IgG (Boehringer Mannheim, Meylan, France), then washed three times with PBS and incubated with extravidin peroxidase (1/2000) . After three washes, the bands were detected with Boehringer chemiluminescent reagent followed by AGFA (Belgium), X ray film exposure.
HSVtk enzymatic assay analysis Cells were lysed in 300 l of Reporter Lysis Buffer (Promega, Charbonnières, France) supplemented with protease inhibitors (Boehringer Mannheim) and then centrifuged for 15 min at 12 000 g and at 4°C. Cell lysates were either assayed immediately or stored in aliquots at −80°C. The supernatants were assayed for the activity of phosphorylating GCV as described, 33, 51 with some modifications. The cell extracts were incubated in a reaction mixture containing 50 mm Tris-HCl pH 8.0, 10 mm Mg Cl 2 , 10 mm ATP, 2 Ci 8-3 H GCV (specific activity, 484.7 Gbq/mmol from Isotopchim, Chimie Fine, Peyruis, France), for 2 h at 37°C. The aliquots were spotted on to a Whatman DE-81 filter disk (Whatman, Maidstone, UK) and then rinsed twice with 70% ethanol, 5 min each, and air dried. The amount of phosphorylated 8-3 H GCV was measured by scintillation counting. Results were defined as pmoles of phosphorylated GCV/h/mg of protein.
In vivo short-term experiments
In this experiment all the rats (n = 32) were killed at the end of GCV treatment (days 24 or 25) for histological and immunohistological studies. Two sequences of GCV treatment were performed: from day 1 after tumor cell implantation to day 25 and from days 10 to 24 (Table 1) . Twenty animals were used to test the ability of Shble to induce cellular inflammatory response. In this second experiment, 10 rats were injected with the C6Shble cell line and 10 rats were injected with C6 tumor cells.
In vivo long-term experiments
In this experiment, as indicated in Table 1 , the rats were implanted with C6 (group 6, n = 10) or C6TK cells (groups 7, 8, 9, 10, n = 45) and tumor evolution was followed by NMR imaging at days 14, 28 and 50 after cell implantation. For group 7, without GCV treatment, and group 8, treated with GCV from day 15 to day 34, the experiment was stopped at day 50 for histological analysis. For groups 6 and 9, without GCV treatment, and group 10, treated with GCV from day 15 to day 34, rats were kept for long-term survival study.
Nuclear magnetic resonance imaging Rats were anesthetized with a mixture of halothane and air (0.8 ml/min flow rate). Halothane concentration was 4% to establish the anesthesia, 2% during installation of the rat in the NMR probe, 0.4-1% for rats with tumors during MRI experiment. The NMR probe consisted of an amagnetic stereotactic head holder and an elliptic surface coil (50 mm × 40 mm). The body temperature of the rats was kept constant throughout the experiment by using a water-circulated heating blanket. MRI was carried out on a 40 cm diameter horizontal bore magnet (2.35 Tesla) interfaced with a MSL spectrometer (Bruker, Wissembourg, France) equipped with an unshielded 12 cm diameter gradient insert. Images of three transverse slices and 10 contiguous coronal slices were acquired. The position of these slices were defined on scout images. The images were acquired using a classical spin-echo (SE) sequence, T2 weighted (TE = 80 ms, TR = 2000 ms). Four averages were used for each phase encoding step, the slice thickness was 1 mm and the field of view was 30 mm. The size of the acquisition matrix was 128 × 64. Fourier transformation and interpolation yielded an image matrix of 128 × 128, giving rise to an in plane resolution of 234 m.
Histological and immunohistological analysis
After death or after rats were killed, brains were removed, frozen and sectioned on a cryotome. Serial sections were stained with hematoxylin and fuschin. Tumor volumes were determined by measuring the tumor area (every 10 sections) using Sigma Scan program and then calculated by the formula: area × number of slices x thickness of slices. The volume of the agarose core was not subtracted from the tumor volume. Immunohistochemical staining was performed using ED1 anti-macrophages, anti-CD4 and anti-CD8 antibodies (Serotec, Kidlington, UK) according to Montero-Menei et al's 52 protocol and diluted at 1/400, 1/200 and 1/100, respectively. Antibody against Factor VIII (Rabbit Polyclonal, Dako, Trappes, France) was diluted at 1/1000.
Statistical analysis
The differences between groups were analyzed by MannWhitney U-test nonparametric statistical analysis and data are expressed as the mean ± s.d. Survival data of rats with brain tumor were presented as Kaplan-Meier plots 53 and the log rank test was applied for statistical analysis.
